Stephen Wiles, MD
Ophthalmology · Kansas City, MONPI 1932136959
Payments from drug & device makers
Across 499 payments — averaging $40.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$12K
- Bausch & Lomb Americas Inc.$2K
- Alcon$705
- Genentech USA, Inc.$618
- Glaukos Corporation$515
- Novartis$351
- plus $4K from 29 others
What the payments were for
- Consulting fees$1,1009%
- Travel & lodging$1,20510%
- Food & beverage$10,03180%
- Education$1001%
- Gifts$1351%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 186 | $11,875 |
| Bausch & Lomb Americas Inc. | 51 | $2,483 |
| Alcon | 44 | $705 |
| Genentech USA, Inc. | 32 | $618 |
| Glaukos Corporation | 11 | $515 |
| Novartis | 9 | $351 |
| Aerie Pharmaceuticals, Inc. | 18 | $347 |
| Sun Pharmaceutical Industries Inc. | 14 | $332 |
| Biogen | 12 | $293 |
| Harrow Eye, LLC | 11 | $286 |
| Tarsus Pharmaceuticals, Inc. | 8 | $285 |
| Mallinckrodt Hospital Products Inc. | 8 | $239 |
| Astellas Pharma US Inc | 11 | $230 |
| Dompe US, Inc. | 10 | $212 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 9 | $187 |
| Kala Pharmaceuticals, Inc. | 8 | $174 |
| Apellis Pharmaceuticals, Inc. | 7 | $159 |
| Sight Sciences, Inc. | 9 | $151 |
| Amgen | 2 | $134 |
| Eyepoint US, Inc. | 10 | $131 |
| Sandoz | 3 | $99 |
| Coherus Oncology, Inc. | 3 | $85 |
| Ivantis, Inc | 4 | $68 |
| Thea Pharma Inc. | 3 | $67 |
| Akorn Operating Company LLC | 3 | $58 |
| Alimera Sciences, Inc. | 2 | $45 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| Biotissue Holdings Inc. | 2 | $44 |
| The Cameron-ehlen Group, Inc. | 1 | $21 |
| Eyevance Pharmaceuticals LLC | 1 | $20 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $17 |
| Alcon Research LLC | 1 | $17 |
| Ocular Therapeutix, Inc. | 1 | $16 |
| Rxsight Inc | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- IC-8 Apthera IOL$1,491
- enVista MX60 IOL$1,491
- STELLARIS ELITE$1,491
- DURYSTA$1,379
- IACCESS$132
- iStent$132
- iStent inject W$132
- XEN GLAUCOMA TREATMENT SYSTEM$122
- TEPEZZA$121
- MIEBO$110
- XIIDRA$110
- iDoseTR$106
- BEOVU$102
How this compares
$20,332 in reported general payments places this provider in the 85th percentile of 286 ophthalmology providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 572 | $247,610 |
| RestasisCyclosporine | 67 | $71,673 |
| CombiganBrimonidine Tartrate/Timolol | 184 | $59,403 |
| RhopressaNetarsudil Mesylate | 74 | $25,837 |
| Prednisolone Acetate | 399 | $20,958 |
| Alphagan PBrimonidine Tartrate | 69 | $20,561 |
| VyzultaLatanoprostene Bunod | 43 | $16,451 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 90 | $15,802 |
| XiidraLifitegrast | 17 | $12,684 |
| MieboPerfluorohexyloctane/Pf | 17 | $12,550 |
| Brimonidine Tartrate | 173 | $12,351 |
| Latanoprost | 835 | $9,273 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 30 | $7,432 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 282 | $4,818 |
| Difluprednate | 43 | $4,353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $11,875 | $399,246892 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra, Miebo | $2,483 | $41,68677 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $347 | $25,83774 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm | $187 | $7,76230 claims |
| AlconSimbrinza | $705 | $7,43230 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 286 ophthalmology providers in Missouri.
Other ophthalmology in Kansas City
- Steven SilversteinKansas City$1.6M
- Joseph TauberKansas City$1.3M
- Andrew MoyesKansas City$1.1M
- Daniel BettisKansas City$258K
- Michelle BoyceKansas City$244K
- Abraham ParkKansas City$223K
- Komal DesaiKansas City$177K
- Manuel CamejoKansas City$63K
- Erin StahlKansas City$10K
- Nancy HolekampChesterfield$2.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.